When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
HCM - Hutchmed Inmagene begin dosing in early-stage study of IMG-007 for eczema
HUTCHMED (China) Limited
Inmagene Biopharmaceuticals and Hutchmed (China) (?HCM) said the first person, based in Australia, was dosed in a global phase 1 trial of IMG-007 to treat adult patients with moderate to severe atopic dermatitis (eczema).
The early-stage trial is a dose-escalation study in healthy volunteers, and a dose-escalation, multiple-dose study in adult patients with moderate to severe atopic dermatitis.